## SENTARA COMMUNITY PLAN (MEDICAID)

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

Drug Requested: Sylvant® (siltuximab) (J2860) (Medical)

MEMBER & PRESCRIBER	INFORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	
Prescriber Name:	
	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Aut	horization may be delayed if incomplete.
Drug Form/Strength:	
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:
	s box, the timeframe does not jeopardize the life or health of the member naximum function and would not subject the member to severe pain.
	ek below all that apply. All criteria must be met for approval. To entation, including lab results, diagnostics, and/or chart notes, must be
<b>Initial Authorization: 12 mont</b>	ths
☐ Member is 18 years of age or o	older
☐ Prescribed by or in consultation with an oncologist, immunologist, and/or infectious disease specialist	
☐ Member has a documented diag	gnosis of Multicentric Castleman Disease (MCD)
<ul> <li>Member is Human Immunodef</li> </ul>	ficiency Virus (HIV) negative and Human Herpesvirus-8 (HHV-8) negative

(Continued on next page)

	Member is currently free of all clinically significant infections and does <b>NOT</b> have evidence of organ failure	
	Provider has submitted complete blood count (CBC) testing which documents <u>ALL</u> the following, prior to the first siltuximab dose:	
	$\Box$ Absolute neutrophil count greater than or equal to 1.0 x10 <sup>9</sup> /L	
	$\Box$ Platelet count greater than or equal to 75 x10 <sup>9</sup> /L	
	☐ Hemoglobin less than or equal to 17 g/dL	
	Requested medication will be used as a single agent	
	Member will <u>NOT</u> receive any live vaccines while being treated with siltuximab	
	Female members must be advised of reproductive potential and counseled on the use of effective contraception during treatment with siltuximab and for 3 months after the last dose is administered	
sup	<b>authorization:</b> 12 months. Check below all that apply. All criteria must be met for approval. To port each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be vided or request may be denied.	
	Provider has submitted clinical documentation which shows no evidence of disease progression/treatment failure	
	Provider has submitted complete blood count (CBC) testing which documents <u>ALL</u> the following, prior to continuation of siltuximab therapy:	
	□ Absolute neutrophil count greater than or equal to 1.0 x 10 <sup>9</sup> /L	
	□ Platelet count greater than or equal to 50 x 10 <sup>9</sup> /L	
	☐ Hemoglobin less than or equal to 17 g/dL	
M	edication being provided by (check applicable box(es) below):	
	Location/site of drug administration:	
	NPI or DEA # of administering location:	
	<u>OR</u>	
□ Specialty Pharmacy – Proprium Rx		
For u	argent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a	

\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria.\*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\*

standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's

ability to regain maximum function.

<sup>\*</sup>Approved by Pharmacy and Therapeutics Committee: REVISED/UPDATED: 7/19/2023